Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I
- 1 April 2006
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (8), 2105-2108
- https://doi.org/10.1016/j.bmcl.2006.01.073
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- New Approaches toward Anti-HIV ChemotherapyJournal of Medicinal Chemistry, 2005
- Reactions of Cyclic Diazoamides:Convenient Synthesis of Dispirocyclic Cyclopropane SystemsSynlett, 2003
- Total Synthesis of (−)‐Spirotryprostatin BAngewandte Chemie-International Edition, 2003
- Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptaseDrug Resistance Updates, 1999
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Delavirdine Mesylate, a Potent Non-Nucleoside HIV-1 Reverse Transcriptase InhibitorAdvances in experimental medicine and biology, 1996
- L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptaseAntimicrobial Agents and Chemotherapy, 1995
- Inhibition of Human Immunodeficiency Virus Type I (HIV-I) Replication by the Dipyridodiazepinone BI-RG-587The Journal of Infectious Diseases, 1991
- Reactivity of oxoindole-.DELTA.3,.alpha.-acrylates toward diazoalkanes: an unusual ring expansionThe Journal of Organic Chemistry, 1978
- Condensed Cyclobutane Aromatic Systems. V. The Synthesis of Some α-Diazoindanones: Ring Contraction in the Indane SeriesJournal of the American Chemical Society, 1958